Zinc copper ratio men: Chaabouni et al., 2026
A cross-sectional study of women with polycystic ovary syndrome found that zinc and copper levels — and the ratio between them — varied with insulin resistance, body mass, and inflammation status. The study cannot establish causation, only association, and the findings in women with PCOS may not translate to men without metabolic dysfunction.
Key takeaways
- Women with PCOS and insulin resistance had elevated copper, zinc, and copper-to-zinc ratio compared to those without insulin resistance.
- Women with PCOS plus body mass excess or subclinical inflammation had lower zinc-to-copper ratios — the opposite pattern.
- This is a cross-sectional study — it captures a snapshot in time but cannot prove that altered trace element levels caused PCOS features or vice versa.
- The study population was women with a specific endocrine disorder; findings may not apply to men or to populations without PCOS.
- The authors recommend caution with supplementation — ratio disturbances go both directions depending on the metabolic context.
The study
Chaabouni et al. published this cross-sectional analysis in the African Journal of Reproductive Health in 2026 (PubMed). The researchers enrolled women diagnosed with PCOS and measured serum zinc and copper levels alongside standard metabolic, inflammatory, and hormonal markers. They stratified participants into subgroups: those with insulin resistance, those with body mass excess, and those with subclinical inflammation. The study did not report total sample size in the abstract, but the design was observational — no intervention, no control group of healthy women, just comparison across PCOS phenotypes. Blood was drawn once; trace element concentrations were measured and correlated with clinical variables. No supplementation was tested. The study assessed associations, not causation.
How to read this study
What this paper does well: It stratifies PCOS patients by metabolic phenotype — insulin resistance, body mass excess, inflammation — rather than treating PCOS as a monolith. That matters because PCOS is heterogeneous; not all women with PCOS have insulin resistance, and not all have inflammation. By looking at subgroups, the authors can see that trace element patterns vary with the underlying metabolic disturbance. They also measured both zinc and copper, not just one, which lets them calculate ratios — a more informative marker than absolute levels alone. The correlations with anthropometric, metabolic, inflammatory, and hormonal variables give context to the trace element changes.
What this paper is missing: The abstract does not report sample size, which makes it impossible to judge statistical power. More importantly, this is a cross-sectional design — a single snapshot. We cannot know if altered zinc or copper levels preceded the metabolic dysfunction (suggesting causation) or if they are a consequence of insulin resistance, inflammation, or hormonal imbalance. The study also lacks a control group of healthy women, so we cannot compare PCOS patients to a baseline population. We do not know if the trace element patterns are specific to PCOS or common to any metabolic stress.
How I'd weight this paper: I treat this as hypothesis-generating, not actionable. The opposing patterns — higher copper-to-zinc ratio in insulin resistance, lower zinc-to-copper ratio in body mass excess — suggest that trace element supplementation in PCOS is not one-size-fits-all. For men without PCOS, the relevance is indirect at best. The study flags that zinc and copper interact with metabolic health, but it does not tell us how to intervene or whether correcting the ratio improves outcomes. I would need randomized supplementation trials with clinical endpoints before changing behavior.
What they found
In women with PCOS and insulin resistance, serum copper, zinc, and the copper-to-zinc ratio were all elevated relative to PCOS patients without insulin resistance. The direction of change — both elements rising — is unusual; typically, copper and zinc move in opposite directions because they compete for absorption. The authors do not report whether the increase in copper outpaced the increase in zinc, which would explain the elevated copper-to-zinc ratio.
In women with PCOS plus body mass excess or subclinical inflammation, the zinc-to-copper ratio was lower — meaning relatively more copper or relatively less zinc. This is the inverse of the insulin resistance pattern. The study found significant correlations between trace element levels and anthropometric variables (body mass index, waist circumference), metabolic markers (fasting insulin, HOMA-IR), inflammatory markers (C-reactive protein), and hormonal variables (testosterone, luteinizing hormone). The abstract does not report correlation coefficients or p-values, so the strength of these associations is unclear.
What it means for the average man
This study does not tell you what your zinc-to-copper ratio should be. It tells you that in women with a specific hormonal disorder, trace element ratios shift with metabolic context — and they shift in opposite directions depending on whether insulin resistance or inflammation dominates. For men, the takeaway is that zinc and copper interact with metabolic health, but the direction of interaction depends on what else is happening in your body. Supplementing zinc in isolation without knowing your copper status — or supplementing copper without knowing your zinc status — risks creating an imbalance. The authors' caution applies: if you are considering trace element supplementation, measure baseline levels first and retest after intervention. Do not assume that more zinc is always better or that a lower copper-to-zinc ratio is always the goal.
The caveats
The study population was women with PCOS, a disorder defined by hyperandrogenism, ovulatory dysfunction, and often insulin resistance. Men do not have PCOS, and men with normal testosterone and metabolic health may respond differently to trace element shifts. The cross-sectional design cannot establish causation — we do not know if altered zinc or copper levels drive metabolic dysfunction or result from it. The abstract does not report conflicts of interest, funding source, or sample size. Without a control group of healthy women, we cannot isolate what is specific to PCOS versus what is common to metabolic stress in general. Other studies in men have shown different patterns; one trial in elderly men found that higher zinc was protective against metabolic syndrome, not associated with it.
Frequently asked questions
Can a cross-sectional study prove that zinc or copper levels cause metabolic dysfunction?
No. A cross-sectional study measures everything at one point in time — trace elements, insulin resistance, inflammation — so it cannot establish which came first. The altered zinc and copper levels in this study could be a cause of metabolic dysfunction, a consequence of it, or a marker of some third factor that drives both. To prove causation, you need a randomized controlled trial where one group supplements zinc or copper and you measure whether metabolic outcomes improve compared to placebo. This study is hypothesis-generating, not proof.
Should I supplement zinc to lower my copper-to-zinc ratio?
Not without measuring your baseline levels first. This study found that the relationship between zinc, copper, and metabolic health goes in opposite directions depending on whether insulin resistance or inflammation is present. Supplementing zinc lowers copper absorption, which can create copper deficiency if you start with low copper. Copper deficiency causes anemia, neutropenia, and bone problems. If you are considering trace element supplementation, get a serum zinc and serum copper test first, then retest after 8-12 weeks to confirm you are moving in the right direction.
Does this study apply to men without PCOS?
Probably not directly. PCOS is a disorder of ovarian function, hyperandrogenism, and often insulin resistance — a metabolic context that does not exist in men. Men with metabolic syndrome share some features (insulin resistance, inflammation), but the hormonal backdrop is different. Other studies in men have found different trace element patterns; for example, higher zinc was protective against metabolic syndrome in one trial of elderly men. This study flags that zinc and copper interact with metabolic health, but the specific associations may not translate across sexes or disease states.
Why do zinc and copper compete, and why does that matter?
Zinc and copper share the same intestinal transporter. When you take high-dose zinc, it occupies the transporter and blocks copper absorption, which is why chronic zinc supplementation (50+ mg/day for months) can cause copper deficiency. The reverse is also true — high copper intake can lower zinc absorption. That is why the ratio matters more than absolute levels of either element alone. The body tightly regulates both, and supplementing one without attention to the other risks creating an imbalance. This study suggests that in PCOS, the balance shifts with metabolic phenotype, reinforcing that blanket supplementation recommendations are likely wrong.
Sources
- Chaabouni K., Jallouli D., Mzid K., et al. Association of serum levels of zinc and copper with pathophysiological features of polycystic ovary syndrome. African Journal of Reproductive Health. 2026. PubMed.
- Prasad AS. Zinc deficiency. BMJ. 2003;326(7386):409-410.
These statements have not been evaluated by the Food and Drug Administration. This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before beginning any supplement regimen.
